The treatment of panic disorder in a clinical setting: A 12-month naturalistic study

Neuropsychobiology

Volumn 36, Issue 1, 1997, Pages 25-31

  Marchesi, C ^a   Ampollini, P ^a   Signifredi, R ^a   Maggini, C ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Agoraphobia; Benzodiazepines; Comorbid depression; Imipramine; Panic disorder

Indexed keywords

BENZODIAZEPINE DERIVATIVE; IMIPRAMINE; LORAZEPAM;

ADOLESCENT; ADULT; AGED; AGORAPHOBIA; ARTICLE; AVOIDANCE BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; TREMOR; XEROSTOMIA;

AGORAPHOBIA; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AROUSAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; IMIPRAMINE; LONG-TERM CARE; LORAZEPAM; PANIC DISORDER; PERSONALITY ASSESSMENT; TREATMENT OUTCOME;

EID: 0030919147     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119356     Document Type: Article

References (39)

1. Lydiard RB, Ballenger JC: Antidcpressant and panic disorder, J Affect Disord 1987; 13:153-168.
2. Judd FK, Norman TR, Burrows GD: Pharmacotherapy of panic disorder, Int Rev Psychiatry 1990;2:399-409.
3. Shear MK: Panic disorder; in Beitman BD, Klerman GL(eds): Integrating Pharmacotherapy and Psychotherapy, Washington, American Psychiatric Press, 1991. pp 143-164.
4. Ballenger JC, Pollack MH, Ross J: Practical approaches to the treatment of panic disorder, J Clin Psychiatry 1996:57:1:45-52.
5. Mavissakalian MR, Percl JM: Imipramine dose-rcsponse relationship in panic disorder with agoraphobia, Arch Gen Psychiatry 1989: 46:127-131.
6. Mavissakalian MR, Perel JM: Imipramine treatment of panic disorder with agoraphobia: Dose ranging and plasma level-response relationships, AmJ Psychiatry 1995:152:673-682.
7. Sheehan DV: Benzodiazepines in panic disorder and agoraphobia, J Affect Disord 1987:13: 169-181.
8. Goldstein S: Sequential treatment of panic disorder with alprazolam and imipramine, Am J Psychiatry 1986; 143:1634.
9. Lydiard RB, Ballenger JC: Panic-related disorders: Evidence for efficacy of the antidepressants, J Anx Disord 1988:2:77-94.
10. Roy-Byme PP, Wingerson D: Pharmacotherapy of the anxiety disorders; in Tasman A (ed): Annual Review of Psychiatry, Washington, American Psychiatric Press, 1992. vol 2. pp 13-32.
11. Modigh K: Antideprcssant drugs in anxiety disorders, Acta Psychiatr Scand 1987;76(suppl 335):57-71.
12. Aronson TA: A naturalistic study of imipra-minc in panic disorder and agoraphobia, Am J Psychiatry 1987;144:1014-1019.
13. Ballenger J: Long-term pharmacologic treatment of panic disorder, J Clin Psychiatry 1991; 52(suppl 2): 18-23.
14. Spitzer RL, Williams JBW, Gibbon M, First MB: Structured Clinical Interview According to DSM-III-R, Washington, American Psychiatric Press, 1990.
15. Pfohl B, Blum N, Zimmerman M, Stangl D: Structured Interview for Personality Disorders, revised version, Iowa City, University of Iowa, 1989.
16. Hamilton M: A rating scale for depression, J Neurol Ncurosurg Psychiatry 1960;23:56-62.
17. Keller M, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott NC, Andreasen NC: The Longitudinal Interval Follow-up Evaluation: A comprehensive method for assessing outcome in prospective longitudinal studies, Arch Gen Psychiatry 1987:49:371-376.
18. Levine J, Schooler NR: Saftee: A technique for the systemat ic assessment of side effects in clinical trials, Psvchopharmacol Bull 1986:22:343-381.
19. Shear MK, Maser JD: Standardized assess-menl for panic disorder research, Arch Gen Psychiatry 1994:51:346-354.
20. Tyrer P, Murphy S, Riley P: The benzodiazepine withdrawal symptom questionnaire, J Affect Disord 1990;19:53-61.
21. Pollack MH, Rosenbaum JF: Benzodiazepines in panic-related disorders, J Anx Disord 1988; 2:95-107.
22. Mavissakalian MR, Perel JM, Michelson LK: The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia, J Clin Psychopharmacol 1984:4:36-40.
23. Mavissakalian MR, Perei JM: Imipramine in the treaimcnt of agoraphobia: Dose-response relationships, Ani J Psychiatry 1985:142: 1032-1036.
24. Mavissakalian MR, Perei JM: Dose response relationship: in Shagass C, Josiassen R, Bridger W, Weiss K, StolTD, Simpson G (eds): Biological Psychiatry, New York, Elsevier, 1985.
25. Sands BE, Creelman WL, Ciraulo DA, Green-blatt DJ, Shader RI: Benzodiazepines: in Ciraulo DA, Shader RI, Grcenblatt DJ, Creelman WL (eds): Drug Interactions in Psychiatry, ed2. Baltimore, Williams &Wilkins, 1995. pp 214-248.
26. Sheehan DV, Coleman JH, Greenblatt DJ, Jones KJ, Levine PH, Orsulack PJ, Peterson M, Schildkraut JJ, Ulogara E, Watkins D: Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment, J Clin Psychopharmacol 1984:4:66-75.
27. Silverman G, Braithwaithe R: Benzodiazepines and tricyclic antidepressant plasma levels, Br Med J 1973:2:18.
28. Deicken RF: Clonazepam-induced reduction in serum desipramine concentrations, J Clin Psychopharmacol 1988:8:71.
29. Rics RK, Wittkowsky AK: Synergistic action of alprazolam with tranylcypromine in drug-resistant atypical depression with panic attacks, Biol Psychiatry 1986:21:519-521.
30. Mavissakalian MR, Michelson LK: Agoraphobia: Relative and combined effectiveness of therapist-assisted in vivo exposure and imipra-minc, J Clin Psychiatry 1986;47:117-122.
31. Noyes R Jr., Clancy J, Hoenk PR, Slymen DJ: The prognosis of anxiety neurosis, Arch Gen Psychiatry 1980:37:173.
32. Coryell W, Noyes R, Clancy J: Panic disorder and primary unipolar depression: A comparison of background and outcome, J Affect Disord 1983;5:311-315.
33. Reich JH: DSM-I1I personality disorders and the outcome of treated panic disorder, Am J Psychiatry 1988:145:1149-1153.
34. Reich JH, Vasilc RG: Effect of personality disorders on the treatment outcome of axis I conditions: An update, J Ncrv Ment Dis 1993:181: 475-484.
35. Marks IM, Gray S, Cohen D, Hill R, Mawson D, Ramm E, Stem RS: Imipramine and brief therapist-aided exposure in agoraphobics having self exposure homework, Arch Gen Psychiatry 1983:40:153-162.
36. Sheehan DV, Ballenger J, Jacobsen G: Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms, Arch Gen Psychiatry 1980:37:51-59.
37. Zitrin CM, Klein DF, Wocmer MG, Ross DC: Treatment of phobias, Comparison of imipra-mine hydrochloride and placebo, Arch Gen Psychiatry 1983:40:125-138.
38. Andersch S, Rosenberg NK, Kullingsjö H, Ottosson JO, Bech P, Bruun-Hansen J, Hanson L, Lorentzen K, Mcllergard M, Rasmussen S, Rev senberg R: Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder, A Scandinavian multicenter study, Acta Psvchiatr Scand 1991:83(suppl) 3651:18-27.
39. Roy-Byme PP, Sullivan MD, Cowley DS, Rics RK: Adjunctive treatment of benzodiazepine discontinuation syndromes: A review, J Psy-chiatrRes 1993:27(suppl 1):143-153.